Sculptor Capital LP Buys Shares of 145,289 Tempus AI, Inc. (NASDAQ:TEM)

Sculptor Capital LP acquired a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 145,289 shares of the company’s stock, valued at approximately $5,085,000. Sculptor Capital LP owned approximately 0.09% of Tempus AI at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Sandia Investment Management LP acquired a new stake in shares of Tempus AI during the second quarter worth approximately $136,000. Northwestern University acquired a new stake in shares of Tempus AI during the second quarter worth approximately $491,000. Squarepoint Ops LLC bought a new position in Tempus AI during the second quarter valued at approximately $633,000. WINTON GROUP Ltd bought a new position in Tempus AI during the second quarter valued at approximately $634,000. Finally, The Manufacturers Life Insurance Company bought a new position in Tempus AI during the second quarter valued at approximately $946,000.

Tempus AI Stock Performance

TEM opened at $51.87 on Friday. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $77.00. The business’s fifty day simple moving average is $49.38.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, August 6th. The company reported ($6.77) EPS for the quarter, missing the consensus estimate of ($4.41) by ($2.36). The firm had revenue of $165.97 million for the quarter, compared to the consensus estimate of $159.10 million. On average, sell-side analysts anticipate that Tempus AI, Inc. will post -6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TEM shares. Piper Sandler started coverage on shares of Tempus AI in a research report on Monday, August 12th. They set a “neutral” rating and a $40.00 price objective on the stock. Bank of America started coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued a “buy” rating and a $41.00 price target on the stock. William Blair started coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued an “outperform” rating on the stock. Morgan Stanley started coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued an “overweight” rating and a $44.00 price target on the stock. Finally, Stifel Nicolaus started coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued a “buy” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.56.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.